ATE393243T1 - Diagnostisches verfahren der mastozytose - Google Patents
Diagnostisches verfahren der mastozytoseInfo
- Publication number
- ATE393243T1 ATE393243T1 AT04715423T AT04715423T ATE393243T1 AT E393243 T1 ATE393243 T1 AT E393243T1 AT 04715423 T AT04715423 T AT 04715423T AT 04715423 T AT04715423 T AT 04715423T AT E393243 T1 ATE393243 T1 AT E393243T1
- Authority
- AT
- Austria
- Prior art keywords
- mastocytosis
- mutation
- detected
- kit
- diagnostic procedure
- Prior art date
Links
- 208000008585 mastocytosis Diseases 0.000 title abstract 3
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 230000035772 mutation Effects 0.000 abstract 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 abstract 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 abstract 2
- 229940124204 C-kit inhibitor Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44986103P | 2003-02-27 | 2003-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE393243T1 true ATE393243T1 (de) | 2008-05-15 |
Family
ID=32927581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04715423T ATE393243T1 (de) | 2003-02-27 | 2004-02-27 | Diagnostisches verfahren der mastozytose |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080025916A1 (de) |
| EP (1) | EP1597398B1 (de) |
| JP (1) | JP2006519220A (de) |
| AT (1) | ATE393243T1 (de) |
| CA (1) | CA2517308A1 (de) |
| DE (1) | DE602004013283D1 (de) |
| WO (1) | WO2004076693A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2535242A1 (en) * | 2003-08-15 | 2005-02-24 | Ab Science | Use of c-kit inhibitors for treating type ii diabetes |
| PL1684750T3 (pl) | 2003-10-23 | 2010-10-29 | Ab Science | 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej |
| EP2361624A1 (de) * | 2005-04-04 | 2011-08-31 | AB Science | Oxazolderivate und Ihre Anwendung als Tyrosinkinase Inhibitoren |
| SG159561A1 (en) | 2005-05-09 | 2010-03-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use |
| CN103342701B (zh) | 2007-02-13 | 2016-09-21 | Ab科学有限公司 | 作为激酶抑制剂的2-氨基噻唑化合物多晶型及其制备方法 |
| US8183263B2 (en) | 2007-05-22 | 2012-05-22 | Achillion Pharmaceuticals, Inc. | Heteroaryl substituted thiazoles |
| US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339100B1 (en) * | 1999-12-29 | 2002-01-15 | The Trustees Of Columbia University In The City Of New York | Methods for inhibiting mastocytosis |
| GB0108606D0 (en) * | 2001-04-05 | 2001-05-23 | Novartis Ag | Organic compounds |
| EP1471907B1 (de) * | 2001-06-29 | 2008-07-16 | AB Science | Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen |
| US20050054617A1 (en) * | 2001-06-29 | 2005-03-10 | Alain Moussy | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| CA2452390A1 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating bone loss |
| EP1434991B1 (de) * | 2001-06-29 | 2007-10-17 | AB Science | C-kit inhibitoren |
| DE60316810T2 (de) * | 2002-08-02 | 2008-07-17 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren |
-
2004
- 2004-02-27 CA CA002517308A patent/CA2517308A1/en not_active Abandoned
- 2004-02-27 AT AT04715423T patent/ATE393243T1/de not_active IP Right Cessation
- 2004-02-27 DE DE602004013283T patent/DE602004013283D1/de not_active Expired - Lifetime
- 2004-02-27 EP EP04715423A patent/EP1597398B1/de not_active Expired - Lifetime
- 2004-02-27 WO PCT/IB2004/000907 patent/WO2004076693A1/en not_active Ceased
- 2004-02-27 JP JP2006502496A patent/JP2006519220A/ja not_active Withdrawn
- 2004-02-27 US US10/547,074 patent/US20080025916A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2517308A1 (en) | 2004-09-10 |
| US20080025916A1 (en) | 2008-01-31 |
| JP2006519220A (ja) | 2006-08-24 |
| EP1597398B1 (de) | 2008-04-23 |
| WO2004076693A1 (en) | 2004-09-10 |
| DE602004013283D1 (de) | 2008-06-05 |
| EP1597398A1 (de) | 2005-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE442592T1 (de) | Detektion und/oder beobachtung von synuclein- assoziierten krankheiten | |
| Cunningham et al. | Development of a condition‐specific quality of life measure for patients with dentofacial deformity: II. Validity and responsiveness testing | |
| DE60312309D1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
| ATE447878T1 (de) | Verfahren und vorrichtung zur augenverfolgung | |
| ATE403750T1 (de) | Methoden und kompositionen zur bewertung von antikörper behandlungen | |
| ATE311876T1 (de) | Hochselektive butyrylcholinesterase inhibitoren zur behandlung und zur diagnose von demenz und alzheimers krankheit | |
| WO2006041678A3 (en) | Pharmaceutical treatment effectiveness analysis computer system and methods | |
| WO2003107252A3 (en) | METHOD AND SYSTEM FOR MONITORING PATIENT CARE | |
| DE69434152D1 (de) | Vorrichtung zur beurteilungshilfe des kardiovaskulären zustandes eines patienten | |
| ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
| CY1110503T1 (el) | Πενταμιδινη για θεραπεια καρκινου | |
| DE60324925D1 (de) | Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck | |
| DE602004013283D1 (de) | Diagnostisches verfahren der mastozytose | |
| ATE557087T1 (de) | Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz | |
| EA200800879A1 (ru) | Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов | |
| SE0301825D0 (sv) | Method and arrangement relating to testing implants | |
| DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| FI933291A0 (fi) | Foerfarande foer paovisning av anti-rna-antikroppar | |
| DE60231896D1 (de) | Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus | |
| ATE430517T1 (de) | Verfahren und geräte zur beobachtung und aufzeichnung von unregelmässigkeiten der makula und des nahen retinafelds | |
| DE602006005635D1 (de) | Vorrichtung und verfahren zum automatischen prüfen der temperaturempfindlichkeit eines patienten | |
| AU2579995A (en) | Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis | |
| EP1611251A4 (de) | Therapeutische, prophylaktische und diagnostische wirkstoffe | |
| ATE556053T1 (de) | Piperidinderivate zur behandlung von alzheimer- krankheit | |
| EP1363528A4 (de) | Verfahren zur diagnose und behandlung von herzerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |